FTRP FIELD TRIP HEALTH LTD

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or “Reunion”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “REUN” at the opening of the market on August 17, 2022.

Trading of the Company’s shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company’s former subsidiary, Field Trip Health & Wellness Ltd. (“FTHW”) into a stand-alone public company listed on the TSX Venture Exchange. Reunion continues to hold a 21.84% interest in FTHW.

For further details on the business of the Company, please refer to the management information circular dated May 20, 2022 and the supplement thereto available on its SEDAR and EDGAR profiles available at or .

About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)

Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

Learn more at , and .

Follow us on Twitter and Instagram: @reunionneuro.

Cautionary Note Regarding Forward-Looking Information 

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at and on the EDGAR section of the SEC’s website at .

Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Reunion Neuroscience:

Joseph del Moral

Media contacts:

McKenna Miller / Nick Opich

KCSA Strategic Communications

Investor contacts:

Phil Carlson / Sophia Bashford

KCSA Strategic Communications

SOURCE Reunion Neuroscience Inc.

 



EN
16/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIELD TRIP HEALTH LTD

 PRESS RELEASE

Reunion Neuroscience Inc. Announces Results of Annual General and Spec...

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “Meeting”). The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 5,073,132, representing 43.57% of the Company’s 11,642,953 outstanding common shares entitled to be voted. All o...

 PRESS RELEASE

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief E...

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment of Greg Mayes as President and Chief Executive Officer. ...

 PRESS RELEASE

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferen...

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate in two upcoming investor conferences in September 2022. H.C. Wainwright 24th Annual Global Investment ConferenceReunion’s management team will present at a virtual fireside chat at the H.C. Wainwright 24th Annual Global I...

 PRESS RELEASE

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Sha...

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled its 2022 Annual General Meeting of Shareholders for September 29, 2022 at 10:00 AM ET. Shareholders of record on August 23, 2022 will be able to vote and ask questions online during the meeting. The Meeting will be...

 PRESS RELEASE

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exc...

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022 TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or “Reunion”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “REUN” at the opening of the market on August 17, 2022. Trading of the Company’s sha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch